ACC/AHA Release 2026 Guideline on Dyslipidemia Management: Earlier Treatment, New Risk Tools, and Lower LDL Targets Recommended

The American College of Cardiology (ACC) and the American Heart Association (AHA) have released the 2026 ACC/AHA Guideline on the Management of Dyslipidemia, introducing several important updates in cardiovascular risk assessment, lipid testing, and lipid-lowering therapy.

Published in the March 2026 issue of Circulation, the new document was developed by a multidisciplinary panel representing several organizations including the American Diabetes Association (ADA), National Lipid Association (NLA), and Preventive Cardiovascular Nurses Association (PCNA).

The new 2026 guideline supersedes the widely used earlier AHA/ACC 2018 cholesterol guidelines and incorporates new findings from big clinical trials, developing lipid biomarkers, and enhanced cardiovascular risk prediction models. Importantly, the statement expands the focus from cholesterol to comprehensive dyslipidemia care, including triglycerides and lipoprotein(a), while emphasizing early detection and lifelong risk reduction.

The 10 key messages from the 2026 guideline include:

1. Prevention starts early in life

One of the most striking changes in the recommendation is the emphasis on early detection and treatment of lipid problems, including screening and preventive interventions for younger population. The goal is to decrease lifetime exposure to atherogenic lipoproteins and avoid the long-term development of ASCVD.

2. PREVENT - A new risk-prediction tool is incorporated

The guideline advises using the PREVENT risk equations to estimate 10- and 30-year cardiovascular risk in persons aged 30-79. This replaces the pooled cohort equations used in previous guidelines, which are expected to improve risk categorization.

3. Treatment may begin earlier in borderline-risk patients

Lipid-lowering therapy can now be explored for primary prevention in people with borderline 10-year ASCVD risk (3-5%), and it should be discussed in those with intermediate risk (5-10%) after shared decision-making between doctors and patients.

4. LDL-C targets yield a good return

The new guideline reintroduces precise LDL-C and non-HDL-C treatment goals, as well as percentage reduction targets, to give clinicians clearer benchmarks for treatment intensification.

5. ApoB testing becomes clinically relevant

The new recommendations suggest measuring apolipoprotein B (ApoB), especially in patients with high triglycerides, diabetes, or when LDL-C may underestimate atherogenic particle burden.

6. Emphasize all adults to undergo one-time Lp(a) testing

Recognizing lipoprotein(a) as an independent genetic risk factor, the guideline recommends at least one lifetime measurement of Lp(a) in adults to identify individuals with inherited higher risk of ASCVD.

7. Coronary calcium scoring (CAC) receives broader consideration

Coronary Artery Calcium (CAC) scoring is indicated to help guide treatment decisions in borderline or intermediate-risk people who are unsure about statin medication.

8. High-risk comorbidities require lipid- lowering therapy (LLT) regardless of LDL-C levels

Adults aged 40 to 75 years with diabetes, stage 3-4 chronic renal disease, or HIV infection should undergo LDL-lowering therapy for primary prevention, even if their baseline LDL-C levels are not high.

9. More aggressive LDL-C targets for secondary prevention

For patients with established ASCVD who are at high risk, the guideline suggests an LDL-C target of less than 55 mg/dL, based on evidence that lower values translate into better cardiovascular protection.

10. Statins remain the cornerstone of therapy; multiple add-on options available

Despite the availability of newer medications, statins remain the first-line treatment for the majority of dyslipidemia patients, and they help to reduce ASCVD risk in people with hypertriglyceridemia. Multiple add-on options can be considered, including ezetimibe, PCSK9 monoclonal antibodies, bempedoic acid, and inclisiran depending on LDL-C reduction, clinical and patient-specific needs.

How do the new 2026 dyslipidaemia guidelines broadly differ from the 2018 version?

Compared to the 2018 ACC/AHA cholesterol guidelines, the 2026 update is broader and more preventive. It shifts the focus from cholesterol management to total dyslipidemia, adds the PREVENT risk calculator, and emphasizes biomarkers like ApoB and lipoprotein(a). Importantly, it reinstates LDL treatment targets and emphasizes early management throughout the life span to prevent cumulative cardiovascular risk.

Abbreviations

PCNA- Preventive Cardiovascular Nurses Association, NLA- National Lipid Association, ADA- American Diabetes Association, ACC – American College of Cardiology; AHA – American Heart Association; ASCVD- Atherosclerotic Cardiovascular Disease; LDL-C – Low-Density Lipoprotein Cholesterol; HDL-C – High-Density Lipoprotein Cholesterol; ApoB- Apolipoprotein B; Lp(a) – Lipoprotein(a); CAC- Coronary Artery Calcium; HIV – Human Immunodeficiency Virus; CKD – Chronic Kidney Disease